Does ADP induced platelet aggregation?
Does ADP induced platelet aggregation?
ADP not only causes primary aggregation of platelets but is also responsible for the secondary aggregation induced by ADP and other agonists. ADP also induces platelet shape change, secretion from storage granules, influx and intracellular mobilization of Ca2+, and inhibition of stimulated adenylyl cyclase activity.
Which drug inhibits platelet activation by ADP?
Clopidogrel (Plavix) inhibits ADP-dependent activation of the glycoprotein IIb/IIIa complex, a necessary step for platelet aggregation. This process results in intense inhibition of platelet function, particularly in combination with aspirin.
What is ADP in platelet aggregation?
Adenosine diphosphate (ADP) is a platelet agonist that causes platelet shape change and aggregation as well as generation of thromboxane A2, another platelet agonist, through its effects on P2Y1, P2Y12, and P2X1 receptors.
What drugs inhibit platelet aggregation?
List of Platelet aggregation inhibitors:
| Drug Name | Avg. Rating | Reviews |
|---|---|---|
| Plavix (Pro) Generic name: clopidogrel | 7.4 | 61 reviews |
| Effient (Pro) Generic name: prasugrel | 7.0 | 20 reviews |
| Aggrenox (Pro) Generic name: aspirin / dipyridamole | 6.9 | 17 reviews |
| Pletal (Pro) Generic name: cilostazol | 7.7 | 5 reviews |
Is Plavix an ADP inhibitor?
Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP- mediated activation of the glycoprotein GPIIb/IIIa complex.
What are ADP blockers used for?
Adenosine diphosphate (ADP) receptor inhibitors are a drug class of antiplatelet agents, used in the treatment of acute coronary syndrome (ACS) or in preventive treatment for patients who are in risk of thromboembolism, myocardial infarction or a stroke.
How do ADP inhibitors work?
ADP binds to the P2Y12 receptor that leads to inhibition of adenyl cyclase and thereby decreases the intracellular levels of cAMP. This reduction of cAMP reduces phosphorylation of vasodilator stimulated phosphoprotein that leads to the activation of the glycoprotein IIb/IIIa receptors.
How do ADP blockers prevent clot formation?
These drugs antagonize the P2Y12 platelet receptors and therefore prevent the binding of ADP to the P2Y12 receptor. This leads to a decrease in aggregation of platelets, prohibiting thrombus formation.
